Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Advanced Colon Cancer

Trial Name: : A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.

Protocol ID: ECOG 7208

Eligibility:

  • Age > 18 yrs.
  • Women must not be pregnant or breast-feeding due to potential danger to the fetus, by therapy including Ramucirumab.
  • Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or agree to abstain from sexual intercourse during their participation in the study and for 3 months following completion of their participation.
  • Histologically documented adenocarcinoma of the colon or rectum.
  • Patients K-ras status must be wild type (not mutated). 
  • Patients must have had prior first-line therapy with oxaliplatin-based fluoropyrimidine-containing chemotherapy and bevacizumab for metastatic colorectal cancer.
  • Patients must meet required laboratory values.
  • No prior therapy with drugs other than oxaliplatin and a fluoropyrimidine plus bevacizumab for this disease.
  • No brain or CNS metastases.
  • No other cancer requiring therapy within the last three years (except in situ carcinoma or non-melanoma skin cancer).

Patient must not have a known allergy to any of the treatment components.

Enrollment: • About 140 people will take part in this study at several medical centers in the United States and Canada.

Benefits:

Taking part in this study may or may not be of direct medical benefit to you. Possible benefits are shrinkage of your tumor, improvement in your symptoms related to your cancer and prolonged survival. We hope the information learned from this study will benefit other patients with colorectal cancer in the future.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jun 3, 2011

Updated: Jan 18, 2013

« Return to Trials